William E. Boden MD, FACC, FAHAVA Boston Healthcare System, Boston University School of Medicine, Boston, Massachusetts
Dr. Boden is Professor of Medicine at Albany Medical College and, in late 2011, assumed duties as the Chief of Medicine at the Samuel S. Stratton Albany VA Medical Center, and as Vice-Chairman, Department of Medicine, at Albany Medical Center, Albany, NY. Previous to this appointment, Dr. Boden was Professor of Medicine and Preventive Medicine at the State University of New York at Buffalo Schools of Medicine and Public Health, and Clinical Chief of the Division of Cardiovascular Medicine. From 2006-2011, he was Director of Cardiovascular Services at Kaleida Health System in Western New York and Chief of Cardiology at Buffalo General and Millard Fillmore Hospitals in Buffalo. He received his medical degree from State University of New York, Upstate Medical Center, Syracuse, NY in 1974 and performed his Internal Medicine training at Boston University Medical Center before completing his fellowship training in Cardiology at Tufts University School of Medicine in Boston. He is board-certified in both Internal Medicine and Cardiovascular Disease. Since 1979, Dr. Boden has held university appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, State University of New York in Buffalo, and currently at the Albany Medical College.
Dr. Boden’s principal research interests include studies in stable ischemic heart disease, post-myocardial infarction (MI) secondary prevention, acute coronary syndromes, and dyslipidemia in post-MI and coronary artery disease (CAD). He has worked extensively in the clinical trials arena of non–ST-segment elevation MI and in assessing the role of calcium antagonists in patients with ischemic heart disease, notably in non-Q-wave MI secondary prevention. Dr. Boden has been involved in clinical research investigator activities as project director, study chairman and co-chairman for multicenter clinical trials, and served as a principal investigator, steering committee member, and consultant for numerous clinical research grant activities funded by the Department of Veterans Affairs, the NIH, and industry. He was the study chairman for the VANQWISH, INTERCEPT, and more recently, the landmark COURAGE Trial (the largest randomized trial comparison of percutaneous coronary intervention [PCI] versus optimal medical therapy in stable CAD patients). He is also study Co-chairman of the NIH-funded AIM-HIGH trial evaluating the long-term role of combination dyslipidemic therapy (niacin and statin vs statin) in CAD patients with low HDL-cholesterol, which recently concluded and was published in December, 2011, as well as a co-PI on the NIH-funded ISCHEMIA Trial, which will begin active enrollment in 2012.
Dr. Boden has lectured widely and written over 380 peer-reviewed publications, original articles, books, chapters, and abstracts. He has been selected as one of the Best Doctors in America continuously since 2003. He is a member of several professional Cardiology organizations and editorial boards of the American Journal of Cardiology, Journal of Cardiovascular Pharmacology and Therapeutics, and Clinical Cardiology. He also serves as an ad hoc journal reviewer for the New England Journal of Medicine, Journal of the American Medical Association, Journal of the American College of Cardiology, Circulation, American Heart Journal, The Lancet, Annals of Internal Medicine, American Journal of Medicine, and Archives of Internal Medicine.
Recent Contributions to PracticeUpdate:
- Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization
- MY APPROACH to Managing Stable Ischemic Heart Disease
- CCTA Findings to Justify Potential Treatment of CAD: Tread Softly
- Prognostic Value of Non-Obstructive and Obstructive CAD Detected by Coronary CT Angiography
- Predicting Outcome in the COURAGE Trial: Coronary Anatomy vs Ischemia